

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO |
|-----------------------------|---------------|----------------------|-------------------------|-----------------|
| 09/925,192 | 08/09/2001 | Dan W. Denney JR. | GENITOPE-06493 | 5113 |
| 75 | 90 10/05/2004 | | EXAMI | NER |
| MEDLEN & CARROLL, LLP | | | YAEN, CHRISTOPHER H | |
| Suite 350 101 Howard Str | eet | | ART UNIT | PAPER NUMBER |
| San Francisco, CA 94105 | | | 1642 | |
| | | į. | DATE MAILED: 10/05/2004 | ı |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | Application No. | Applicant(s) | | | |
|--|--|---|--|--|--|--|
| Office Action Summary | | 09/925,192 | DENNEY, DAN W. | | | |
| | | Examiner | Art Unit | | | |
| | | Christopher H Yaen | 1642 | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | | |
| THE - Exte after - If the - If NC - Failu Any | ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b). | 36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE | nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133). | | | |
| Status | | • | | | | |
| 1)🛛 | Responsive to communication(s) filed on 26 Ja | nuary 2004. | | | | |
| 2a)□ | This action is FINAL . 2b) ☐ This | action is non-final. | · | | | |
| 3)□ | 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | | |
| Dispositi | on of Claims | • | | | | |
| 5) 6) 7) | Claim(s) <u>25-39</u> is/are pending in the application 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>25-39</u> are subject to restriction and/or | vn from consideration. | · | | | |
| Applicati | on Papers | · | | | | |
| 9)[| The specification is objected to by the Examine | г. | | | | |
| 10) | 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | |
| | Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | |
| 11)[| Replacement drawing sheet(s) including the correcting The oath or declaration is objected to by the Extension is a specific to be supported to be the Extension of the correction of the correct | | · · · · · · · · · · · · · · · · · · · | | | |
| Priority ι | ınder 35 U.S.C. § 119 | | • | | | |
| 12)[_] a)[| Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau see the attached detailed Office action for a list of | s have been received. s have been received in Application ity documents have been receive (PCT Rule 17.2(a)). | on No d in this National Stage | | | |
| Attachmen | t(s) | | | | | |
| 1) 🔲 Notic | e of References Cited (PTO-892) | 4) Interview Summary (| (PTO-413) | | | |
| 3) 🔲 Inform | e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date | Paper No(s)/Mail Da | | | | |

Application/Control Number: 09/925,192 Page 2

Art Unit: 1642

DETAILED ACTION

Re: Denney DW

Priority Date: May 1, 1998

1. Upon further review, the restriction requirement made on 8/24/2004 is vacated in favor of a new restriction requirement set forth herein.

2. Claims 1-24 are canceled without prejudice.

3. Claims 25-39 are newly added and pending.

Election/Restrictions

4. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claims 25-29, drawn to a method of co-amplifying recombinant oligonucleotides comprising the steps of providing 2 vectors comprising recombinant oligonucleotides and a T-lymphoid cell line; introducing said vectors into said cell line; introducing the cell line into an aqueous solution, and identifying a cell capable of growth in said solution, classified in class 435, subclass 69.2, for example.

II. Claims 30-34, drawn to a method of co-amplifying recombinant oligonucleotides comprising the steps of providing 3 vectors comprising recombinant oligonucleotides and a T-lymphoid cell line; introducing said vectors into said cell line; introducing the cell line into a first aqueous solution; identifying a cell capable of growth in said first solution;

Art Unit: 1642

introducing said cells into a second solution; and identifying a cell capable of growth in said second solution, classified in class 435, subclass 69.7.

III. Claims 35-39, drawn to a method of producing a vaccine for treatment of B-cell Lymphoma comprising the steps of providing a malignant cell isolated from a B-cell lymphoma, a amplification vector comprising an oligonucleotides, and a T-cell lymphoid parental cell line; isolating from malignant cell nucleotide sequences; inserting said nucleotide sequences from malignant cell into a first and second expression vector; introducing said first vector and second expression vectors into said parental cell line to generate a transformed cell; introducing the transformed cell into a first aqueous solution; and identifying a transformed cell capable of growth in first aqueous solution, classified in class 435, subclass 69.3.

The inventions are distinct, each from the other because of the following reasons:

5. Inventions I-III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The instant specification does not disclose that these methods would be used together. The methods of groups I-III are all unrelated as they comprise distinct steps and utilize different products which demonstrates that each method has a different mode of operation. For example, the invention of group I comprises the use of 2 vectors while that of group II comprises the use of three type of vectors. Both groups I-II are drawn to methods of co-amplification, while the method of group III is drawn to a method of

Application/Control Number: 09/925,192

Art Unit: 1642

producing a vaccine. Each invention performs the function using structurally and functionally divergent material. Moreover, the methodology and materials necessary for the inventions of group I and II differ significantly for each of the materials. While the purpose of the methods of groups I-II and III differ in outcome and desired use.

Therefore, each method is divergent in materials and steps. For these reasons the Inventions I-III are patentably distinct.

Furthermore, the distinct steps and products require separate and distinct searches. The inventions of Groups I-III have a separate status in the art as shown by their different classifications. As such, it would be burdensome to search the inventions of Groups IV, V and VI together.

6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 571-272-0838. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/925,192

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christopher Yaen Art Unit 1642 September 30,2004

> GARY NICKOL PRIMARY EXAMINER